Skip to content
Screener

McKesson MCK Prescription Technology Solutions — Subtotal

Similar metrics at other companies

ESAB logo
ESABAmericas: — Subtotal
$10.37M
ESAB logo
ESABEMEA and APAC Segment — Subtotal
$35K
Intercontinental Exchange logo
ICEOrigination technology — Description of timing
$0
Duos Technologies Group, Inc. logo
DUOTTechnology Solutions — Revenue
$562.45K+544%
CSP logo
CSPITechnology Solutions — Revenue
$15.66M+25.3%
Duos Technologies Group, Inc. logo
DUOTTechnology Solutions — Revenue
$562.45K+544%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept mck:GrossProfitNetOfExpensesIncludingOtherIncome.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Segment operating profit
North American Pharmaceutical$903$594
Oncology & Multispecialty325212
Prescription Technology Solutions226253
Medical-Surgical Solutions122221
Other13
Subtotal1,5761,293
Corporate expenses, net (6)(191)(193)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's prescription technology solutions — subtotal?
McKesson (MCK) reported prescription technology solutions — subtotal of $226M in Q2 2026.
How has McKesson's prescription technology solutions — subtotal changed year-over-year?
McKesson's prescription technology solutions — subtotal decreased by 10.7% year-over-year, from $253M to $226M.
What is the long-term trend for McKesson's prescription technology solutions — subtotal?
Over 2 years (2024 to 2026), McKesson's prescription technology solutions — subtotal has grown at a 11.8% compound annual growth rate (CAGR), from $835M to $1.04B.
What does prescription technology solutions — subtotal mean?
This metric serves as an intermediate financial subtotal for the Prescription Technology Solutions segment, often representing operating income or a similar performance measure before specific corporate allocations. It provides a view of the segment's profitability before accounting for centralized corporate overhead. It is essential for evaluating the segment's core operational health.

Ask your AI about McKesson's prescription technology solutions — subtotal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude